Skip to main content
CellaVision logo

CellaVision — Investor Relations & Filings

Ticker · CEVI ISIN · SE0000683484 LEI · 529900IUBZBZ0HXFJ114 ST Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2012-10-26 Interim / Quarterly Rep…
Country SE Sweden
Listing ST CEVI

About CellaVision

https://www.cellavision.com/

CellaVision is a medical technology company that provides digital solutions for cell morphology in hematology. The company specializes in automating and standardizing the analysis of blood and other body fluids for both human and veterinary applications. Its core offerings include a complete system of analyzers, instruments, software, and reagents designed for hematology laboratories of all sizes. By utilizing patented technology that integrates automated microscopy, advanced image analysis, and artificial intelligence, CellaVision's systems digitize the traditional manual review of blood smears. This automation enhances laboratory workflow efficiency, improves diagnostic accuracy, and facilitates remote collaboration among healthcare professionals, advancing diagnostic certainty.

Recent filings

Filing Released Lang Actions
CellaVision AB: Delårsrapport januari - september 2012
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive quarterly financial report for CellaVision AB covering the period from January 1 to September 30, 2012. It includes detailed financial statements (income statement, cash flow, balance sheet items), management commentary on business performance, regional market analysis, and research and development updates. It is not an announcement of a report (RPA) or a simple earnings release (ER), as it provides substantive financial data and analysis for the interim period. Therefore, it is classified as an Interim/Quarterly Report. 9M 2012
2012-10-26 Swedish
CellaVision AB: Interim report January - September 2012
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report covering the period from January 1 to September 30, 2012. It includes detailed financial statements (Net sales, operating profit, earnings per share), key ratios, management commentary from the CEO, and analysis of geographical markets and R&D activities. It is clearly an interim financial report for the first nine months of the fiscal year, not an announcement of a report or a standalone audit. 9M 2012
2012-10-26 English
CellaVision inleder distributionsavtal med Siemens
M&A Activity Classification · 1% confidence The document is a press release announcing a distribution agreement between CellaVision and Siemens Healthcare Diagnostics, effective January 1, 2013. It details the scope of the agreement (global sales of digital microscopy solutions in hematology) and includes quotes from the CEOs of both companies. The text concludes with boilerplate information about both companies and a statement indicating the information was released for public disclosure on October 4, 2012, under securities market regulations. This type of announcement, detailing a significant business event (a major partnership/distribution deal) that is not a standard periodic financial report (like 10-K or IR) or a specific corporate action (like dividend or share issue), typically falls under general regulatory announcements or news releases. Since there is no specific category for 'Business Partnership Announcement' and it is a formal release of material information, the most appropriate classification is 'Regulatory Filings' (RNS) as a general regulatory announcement, or potentially 'Capital/Financing Update' (CAP) if the deal significantly impacts financing, but RNS is safer for general material news releases not covered elsewhere. Given the context of a formal announcement of a material business development, RNS is the best fit among the provided options, as it functions as a general regulatory disclosure.
2012-10-04 Swedish
CellaVision Announces Distribution Agreement with Siemens for Digital Microscopy Hematology Solutions
Regulatory Filings Classification · 1% confidence The document announces a significant business event: the signing of a supply, distributorship, sales, and service agreement between CellaVision and Siemens Healthcare Diagnostics regarding digital microscopy hematology solutions. This is a strategic partnership announcement concerning future sales and distribution, not a routine financial report (like 10-K, IR, ER) or a standard regulatory filing update (like DIRS, DIV, MRQ). It details a major commercial transaction that impacts the company's operations and market reach. Among the provided codes, 'TAR' (M&A Activity) is for mergers/takeovers, which this is not. 'CAP' (Capital/Financing Update) is for fundraising/capital structure changes, which this is not. The closest fit for a major strategic commercial agreement that isn't explicitly covered by other codes (like M&A) is often categorized under general strategic announcements. Since this is a major commercial agreement impacting sales and distribution, and it is not a standard financial report, dividend notice, or insider trade, it falls best under a general strategic/regulatory announcement category. Given the options, and recognizing this is a material event disclosure, it most closely resembles a significant corporate action announcement. Since there is no specific 'Strategic Partnership' code, and it is not a standard financial filing, I will evaluate if it fits 'RNS' (Regulatory Filings - general/fallback) or if it implies a change in capital/financing structure (CAP). It is primarily a commercial agreement. In many databases, major commercial agreements that don't involve M&A are often classified as general regulatory news or strategic updates. Given the options, and since it is a material disclosure required by Swedish securities law ('This information is disclosed by CellaVision AB (publ) pursuant to the Swedish Securities Market Act...'), 'RNS' (Regulatory Filings/General Announcement) is the most appropriate fallback for a material, non-financial report announcement that doesn't fit the specific transaction types (like DIV, DIRS, TAR).
2012-10-04 English
CellaVision får sin första order från veterinärmarknaden
Regulatory Filings Classification · 1% confidence The document is a press release announcing a specific business event: CellaVision receiving its first order for its veterinary analysis instrument in North America. It details the strategic value of the order, the product specifications, and the target market. This type of announcement, which is not a formal regulatory filing (like 10-K, IR, or ER) but rather a general corporate update about a significant business development (a new customer/market entry), fits best under the general 'Regulatory Filings' category (RNS) as a catch-all for non-standard, yet important, corporate news, or potentially a general 'Capital/Financing Update' (CAP) if the order implied significant immediate revenue, but RNS is safer for general news releases. Given the options, RNS (Regulatory Filings) is the most appropriate fallback for a general business news announcement that doesn't fit the specific financial report or management change codes. It is too detailed for a simple RPA and is not a formal financial report.
2012-08-28 Swedish
CellaVision receives first order from the Veterinary market
Regulatory Filings Classification · 1% confidence The document announces a specific business event: CellaVision receiving its first order for the CellaVision ® DM96 Vet System in the North American Veterinary market. It includes quotes from the CEO about the strategic value of this order and provides background information about the product and the company. This is not a formal regulatory filing (like 10-K, IR, or ER), nor is it a presentation (IP) or a transcript (CT). It is a specific business update or announcement that doesn't fit the defined categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP). Given the nature of the announcement—a specific business development/contract win—and the lack of a better fit among the specific categories, it most closely aligns with a general regulatory announcement or news release. Since 'Regulatory Filings' (RNS) is defined as the fallback for miscellaneous filings that do not neatly fit, and this is a specific, non-financial-result-focused announcement, RNS is the most appropriate classification.
2012-08-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.